Patent Cooperation Treaty

Seegene Reinforces Commitment to Strong ESG Management with 100% Recyclable, Styrofoam-Free Shipping Boxes

Retrieved on: 
Wednesday, October 18, 2023
Supply Chain Act, Temperature, ESG, International Safe Harbor Privacy Principles, Dry ice, Organization, PCR, Styrofoam, PET, ISTA, Ministry, Supply, Computer programs and the Patent Cooperation Treaty, Environment, PCT, Transport, Ministry of Environment (South Korea), Ecosystem, Forest Stewardship Council, Patent Cooperation Treaty, FSC, European, Philosophy, Climate change, Rare-earth element, Tissue paper, EU

This initiative is part of Seegene's ongoing commitment to good environmental, social, and corporate governance (ESG).

Key Points: 
  • This initiative is part of Seegene's ongoing commitment to good environmental, social, and corporate governance (ESG).
  • Seegene's eco-friendly shipping box is composed of 12-paper layers, biodegradable films, recycled PET packaging, a vacuum insulation panel, dry ice, and ice packs.
  • Each of Seegene's eco-friendly shipping box can hold up to 24 kits –– 30% more than the existing Styrofoam packaging allows.
  • "We will continue to carry out eco-friendly activities in line with our ESG philosophy, which reflects a social consensus."

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK

Retrieved on: 
Thursday, October 12, 2023
Psilocybin, University, MAR, OTC, European Union (Withdrawal) Act 2018, Health care, Investigational New Drug, CDI, Interest, MDMA, PTSD, Indian stock exchange, Novel, Biotechnology, Half-life, Financial Conduct Authority, CREST, Mental health, Issuer, Admission, FSE, PCT, Access, ISIN, NEO, Patent Cooperation Treaty, MYIG, Pharmaceutical industry, Security (finance), EU

Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.

Key Points: 
  • Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.
  • The Companies various families of Novel 2nd generation molecules are showing significant improvements over the first generation of psychedelic treatments.
  • Josh Bartch, CEO of the Company stated, “We are incredibly excited to list our securities for trading in the UK on the AQSE Growth Market.
  • This announcement, together with any documents incorporated by reference, shall be deemed to constitute an admission document for the purposes of the AQSE Growth Market Rules for Issuers – Access.

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings

Retrieved on: 
Tuesday, October 10, 2023
Psilocybin, University, MAR, OTC, European Union (Withdrawal) Act 2018, Health care, Investigational New Drug, CDI, Interest, MDMA, PTSD, Indian stock exchange, Novel, Half-life, Financial Conduct Authority, CREST, Mental health, Issuer, Admission, CSE, PCT, Access, ISIN, Patent Cooperation Treaty, MYIG, Pharmaceutical industry, Security (finance), EU

Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.

Key Points: 
  • Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.
  • The Companies various families of Novel 2nd generation molecules are showing significant improvements over the first generation of psychedelic treatments.
  • Josh Bartch, CEO of the Company stated, “We are incredibly excited to list our securities for trading in the UK on the AQSE Growth Market.
  • This announcement, together with any documents incorporated by reference, shall be deemed to constitute an admission document for the purposes of the AQSE Growth Market Rules for Issuers – Access.

Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity

Retrieved on: 
Wednesday, October 4, 2023
Patent, Sigyn, United States Patent and Trademark Office, Survival, Cancer, Toxicity, Patent Cooperation Treaty, PCT, REDUCE, Patient, SAN, United, Health, Therapy, Death, Pharmaceutical industry

Chemotherapy is the most commonly administered drug to treat cancer, the second leading cause of death in the United States.

Key Points: 
  • Chemotherapy is the most commonly administered drug to treat cancer, the second leading cause of death in the United States.
  • Achievement of this objective will likely improve treatment outcomes yet reduce treatment toxicity and long-term health consequences associated with chemotherapy administration.
  • Post infusion of chemotherapy, Sigyn Therapeutics designed ChemoPureTM to extract off-target drug agents from the bloodstream as a means to further reduce patient toxicity.
  • Sigyn Therapeutics previously disclosed that a related provisional patent application was filed with the United States Patent and Trademark Office (“USPTO”).

Aquis Stock Exchange: Application for Admission Announcement

Retrieved on: 
Wednesday, September 27, 2023
University, Investigational New Drug, Patent Cooperation Treaty, PCT, THAN, PAR, ANY, CLASS, Safety, Pharmaceutical industry, Security (finance)

The Company’s medical and scientific advisory board is building out an R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems.

Key Points: 
  • The Company’s medical and scientific advisory board is building out an R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems.
  • Further, the Company has designed several
    libraries of novel molecules believed to have enhanced safety and efficacy profiles.
  • The Company has a comprehensive intellectual property strategy covering novel molecules, drug formulations, delivery mechanisms, and methods of production.
  • The Company believes this covers all described drug development activities in our named pipeline and clinical trials.

PharmAla Receives First Office Action for PharmAla-1 PCT Filing

Retrieved on: 
Monday, September 25, 2023
BIO, Intellectual property, Ontario Centre of Forensic Sciences, Partnership, CSE, University, P-1, Prior art, Medicine, University of Arkansas for Medical Sciences, Medication, MDXX, Innovation, Research, Patent Cooperation Treaty, PCT, CNS, Central nervous system, OTC, Toxicology, MDMA, Pharmacology, Safety, Pharmaceutical industry

VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has received the first office action from the Patent Cooperation Treaty (PCT) filing for the company’s novel PharmAla-1 (P-1) molecule.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has received the first office action from the Patent Cooperation Treaty (PCT) filing for the company’s novel PharmAla-1 (P-1) molecule.
  • “The generation of novel intellectual property is incredibly important for drug discovery companies like PharmAla.
  • This First Office Action for P-1 shows that our drug discovery pipeline yields novel, inventive molecules with significant value as neuropsychiatric therapeutics,” said Nick Kadysh, CEO, PharmAla Biotech.
  • “Our development pipeline, which can yield new molecules appropriate for pre-clinical development, is an incredible asset for PharmAla.

New PlyBy™ Messaging System Guarantees a Fast Reply™

Retrieved on: 
Tuesday, September 12, 2023
Patent Cooperation Treaty, WhatsApp, Partnership, Fast, Gmail, Patent, Yahoo!, Messenger, Mail

OVERLAND PARK, Kan., Sept. 12, 2023 /PRNewswire/ -- PlyBy.com announces the release of a new messaging product called PlyBy™, that uses patent pending technology to guarantee a Fast Reply™ from electronic messages.

Key Points: 
  • OVERLAND PARK, Kan., Sept. 12, 2023 /PRNewswire/ -- PlyBy.com announces the release of a new messaging product called PlyBy™, that uses patent pending technology to guarantee a Fast Reply™ from electronic messages.
  • A user sends a message, and then they can wait…and wait…and wait…and sometimes never get a reply at all.
  • It's slow and often ineffective, with no solution to getting a fast response from messages sent…until now.
  • Ask your social network for PlyBy, visit PlyBy.com for more information and follow online for updates on exciting new partnership announcements.

Patent Awarded for Primary Template-Directed Amplification, Further Strengthening BioSkryb Genomics’ Core Technologies

Retrieved on: 
Thursday, August 17, 2023
General Health, Health, Science, Other Science, Research, Patent, DNA, PTA, Genomics, Cardiovascular disease, Cancer, DSM-IV codes, Mosaic, Proteome, Patent Cooperation Treaty, Fertilisation, Transcriptome, Chemistry, Genome, Biology, Entrepreneurship, Bias, Artifact, Disease, Pharmaceutical industry, Antibiotics

The patent is exclusively licensed to BioSkryb by St. Jude Children’s Research Hospital.

Key Points: 
  • The patent is exclusively licensed to BioSkryb by St. Jude Children’s Research Hospital.
  • Primary template-directed amplification was invented to address these challenges by providing a highly accurate, scalable, and efficient nucleic acid amplification and sequencing method for research, diagnostics, and treatment.
  • “This patent serves as not only as a cornerstone of BioSkryb’s IP portfolio, but as the foundation of our best-in-class single-cell analysis products,” said Suresh Pisharody, CEO, BioSkryb Genomics.
  • There are 58 pending patent applications, including 12 in the United States, 39 international applications, and 7 applications filed under the Patent Cooperation Treaty.

NEO Battery Materials Selected to Intellectual Property Support Program by South Korean Government Organization

Retrieved on: 
Thursday, July 27, 2023
Defamation, Intellectual property, EV, Patent Cooperation Treaty, IP, PCT, Korean Intellectual Property Office, Consultant, Korea, Silicon, NEO, Yahoo! Finance

TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTCQB: NBMFF)

Key Points: 
  • TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTCQB: NBMFF)
    Expanding IP Strategy through New Patents, PCT Application Support, and Increasing Collaborations with South Korean Battery Industry Players
    NEO Battery Materials Ltd. (“NEO” or the “Company”), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce that NBM Korea Co. has been selected as a recipient of the Intellectual Property Support Program administered by the Korea Invention Promotion Association (“KIPA”), an affiliated organization of the federal Korean Intellectual Property Office (“KIPO”).
  • KIPA’s Intellectual Property Support Program aims to actively support small and medium-sized enterprises to establish exclusive rights and intellectual property (“IP”) to each firm’s proprietary technologies.
  • Selected among 10 IP-based companies, NEO will receive a grant and pro-bono technology consulting to strengthen market competitiveness by implementing new R&D directions and securing indisputable patents.
  • Along with KIPA’s consultants, NEO Battery Materials will strengthen the IP portfolio by patenting innovative processes, analyze competitors’ technologies to develop IP dispute mitigation strategies, and increase collaborations with EV battery industry players.

NurExone Biologic Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery

Retrieved on: 
Thursday, July 20, 2023
Real-time, EV, 3D, FSE, LPS, Patent Cooperation Treaty, Attention, Inflammation, Cell, PCT, Microsoft Exchange Server, NRX, EVS, TEL, Ren, Seminal vesicles, 3D bioprinting, Patent, Immune system, B cell, Fig, RAW, HPRT, Vaccine, 4-Hydroxy-TEMPO, Technion – Israel Institute of Technology

TORONTO and TEL AVIV, Israel, July 20, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in extracellular vesicles (EVs) functionality.

Key Points: 
  • TORONTO and TEL AVIV, Israel, July 20, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in extracellular vesicles (EVs) functionality.
  • Leveraging its proprietary and patented 3D-Flow production, the Company has achieved significantly enhanced EV functionality.
  • Through state-of-the-art production methodologies, NurExone aims to unlock the full potential of EVs as powerful therapeutic tools.
  • This is critical to ensure targeted delivery of therapeutic cargo to specific cell types, maximizing the potential of EVs as drug delivery vehicles.